Leaps by Bayer

Indapta Therapeutics is a privately held biotechnology company focused on developing a natural killer (NK) cell therapy platform aimed at treating both blood and solid tumor cancers. The company specializes in a proprietary off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the effectiveness of antibody therapies. Through its innovative approach, Indapta Therapeutics seeks to provide healthcare providers with advanced treatment options for patients suffering from cancer, leveraging the potent antibody-dependent cellular cytotoxicity (ADCC) activity of its NK cell therapy.

One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.

Nuvig Therapeutics is focused on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function, particularly following inflammation. The company is building a pipeline of novel immune therapeutics specifically designed for chronic inflammatory and autoimmune diseases. By leveraging natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options available to healthcare providers and improve patient outcomes.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Pairwise Plants is an agricultural gene editing company based in San Diego, California, focused on enhancing crops such as corn, soybeans, wheat, cotton, and canola. Founded in 2017 by a team of experts in food technology and genetics, Pairwise aims to improve the quality and nutritional value of fruits and vegetables, including leafy greens, berries, and stone fruits. The company collaborates with food and agriculture organizations to provide innovative solutions for both row and specialty crops. Pairwise holds licenses for advanced gene editing technologies from prestigious institutions, enabling the development of new crop varieties. With a commitment to building a healthier world through better food, Pairwise anticipates launching its first products in the coming years.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Summer Health is a provider of pediatric telehealth services designed to simplify access to healthcare for families. The company enables timely communication with board-certified pediatricians through a text-based platform, allowing users to receive expert answers and reliable advice quickly. Summer Health's services include health tracking and personalized healthcare plans, ensuring that patients can obtain necessary care within minutes. By leveraging digital technology, Summer Health aims to enhance the healthcare experience for families navigating health concerns.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

9amHealth is a healthcare service provider that aims to deliver comprehensive medical support for chronic conditions such as diabetes, hypertension, and hyperlipidemia. The company offers personalized care plans, prescription medication, at-home lab tests, and unlimited virtual visits, ensuring that patients have direct access to affordable and compassionate care. By redesigning all care elements into a single digital service, 9amHealth caters to the modern realities of patients' lives, making healthcare always available and convenient, even for those without insurance. Its focus on chronic conditions highlights its commitment to improving the health and well-being of customers in the United States.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, an important component in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. The company has a pipeline of next-generation TYK2 inhibitors, which includes a candidate designed to penetrate the brain for the treatment of multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical candidate aimed at addressing immune-mediated dermatologic diseases. Sudo Biosciences aims to provide effective and affordable treatment options for patients suffering from these conditions.

Jixing Pharmaceuticals is a global biotechnology company focused on developing and commercializing innovative therapeutics for cardiovascular and ophthalmic diseases. The company has a diverse pipeline that includes treatments for conditions such as hypertrophic cardiomyopathy, heart failure, presbyopia, hypertension, and dry eye disease. A key aspect of their development efforts includes a small molecule cardiac myosin inhibitor, in-licensed from Cytokinetics, specifically designed to treat hypertrophic cardiomyopathy. Jixing Pharmaceuticals aims to provide effective treatments for patients in China, addressing significant unmet medical needs in the realms of cardiovascular and ophthalmic health.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

65LAB focuses on scientific advancement to create new therapeutic companies and lifesaving medicines.

Rantizo, Inc. is a company that specializes in the development and sale of agricultural drones and related equipment, including trailers, sprayers, spreaders, and battery chargers. Founded in 2018 and based in Iowa City, Iowa, Rantizo offers precision spraying services for crops using an innovative electrostatic spraying technique. This technology ensures even coverage of pesticides and chemicals, addressing common challenges faced by farmers in applying these substances. Additionally, Rantizo integrates software solutions with drone manufacturers and agronomy systems to enhance large-scale agricultural operations, facilitating efficient mapping, compliance, and coordination of spraying needs. Through its products and services, Rantizo aims to streamline agricultural practices and improve crop management for farmers.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

ReCode Therapeutics is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company employs a unique non-viral lipid nanoparticle platform that facilitates the precise delivery of nucleic acid and protein payloads to specific organs and tissues, enhancing the effectiveness of genetic therapies. This selective organ targeting (SORT) technology allows for the administration of corrective or disease-modifying treatments beyond the liver, addressing the challenges faced by traditional gene therapy methods. By harnessing these innovative techniques, ReCode Therapeutics aims to provide new therapeutic options for patients suffering from rare and life-limiting respiratory diseases.

Guardian Agriculture specializes in developing autonomous electric vertical takeoff and landing (eVTOL) systems tailored for precision agriculture. Their innovative technology empowers farmers by providing automated aerial crop protection services, significantly enhancing operational efficiency while minimizing environmental impact. The eVTOL system utilizes lithium battery power to ensure safe and effective application over farm fields. Additionally, it captures valuable data to help farmers refine their chemical usage and improve crop sustainability. By integrating aerial utility services with precision agriculture, Guardian Agriculture aims to support growers in extending their operational reach and achieving more sustainable farming practices.

ChrysaLabs, founded in 2017 and based in Montreal, Canada, specializes in the development of innovative technology for real-time soil fertility assessment. The company offers a portable probe that accurately measures soil nutrients and health directly in the field, allowing producers and agronomists to make informed decisions regarding fertilizer management. This advanced optical technology evaluates soil properties at various depths and requires no prior preparation, facilitating immediate access to critical data. In addition to the probe, ChrysaLabs provides a management platform that enables users to access this information and take appropriate actions to optimize crop yield and soil health.

Andes develops an integrated microbial technology to help accelerate crop growth. Its technology is combined with artificial intelligence to develop its seeds while reducing input costs and environmental footprints and helps farmers to boost their agricultural output and income. Andes was founded in 2018 and is headquartered in Alameda, California.

Fork & Good is a Brooklyn-based food company founded in 2018 that focuses on developing a sustainable approach to food production. The company specializes in cultivated meat, which is made by growing real meat cells to create pure animal proteins and fats. These products are designed to be clean, traceable, and flavorful, providing consumers with affordable and healthy food options. Fork & Good aims to contribute to a more sustainable food system by offering alternatives that align with modern dietary preferences and environmental considerations.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By exploring the unique aspects of the bat genome, the company aims to identify and develop therapeutics for a variety of diseases. Paratus Sciences seeks to unlock the secrets of bat biology to facilitate innovative treatments, ultimately helping patients combat the health challenges they encounter.

EarthOptics is a company focused on sustainable agricultural management through the development of a global soil cloud platform. Utilizing advanced sensors and machine learning, EarthOptics creates highly accurate soil maps by analyzing far fewer soil samples. The platform provides detailed insights into various soil attributes, including compaction, fertility, and carbon levels. This technology empowers farmers, ranchers, and land managers to make informed decisions that enhance profitability and sustainability in soil management. Additionally, EarthOptics offers near-real-time actionable data that aids in monitoring soil health, benefiting both agricultural practices and carbon credit verification efforts.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and farm revenues while addressing challenges such as drought. The company offers Source, a solution that enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby helping growers optimize crop performance sustainably. Additionally, Sound Agriculture focuses on improving photosynthesis, water capture, and crop efficiency, contributing to healthier and more flavorful food while reducing waste. Founded in 2012 and based in Emeryville, California, the company employs molecular discovery and life science approaches to create climate-resilient crops, ultimately enhancing productivity for farmers. Originally known as Asilomar Bio, Inc., it rebranded to Sound Agriculture Company in September 2018.

NuCicer is focused on transforming chickpeas from a niche ingredient into a staple superfood by developing new varieties with enhanced agronomic and quality traits. The company specializes in producing chickpeas that feature increased protein content, improved flavor, and tailored nutritional properties. Utilizing a diverse chickpea breeding library alongside a proprietary breeding innovation platform that integrates plant genetics and machine learning, NuCicer aims to address the growing demands for nutritious and sustainable food sources. Their efforts not only enhance the nutritional value of chickpeas but also aim to reduce the environmental impact of agriculture, supporting the needs of the alternative-meat sector and promoting a more sustainable food system.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

ReCode Therapeutics is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company employs a unique non-viral lipid nanoparticle platform that facilitates the precise delivery of nucleic acid and protein payloads to specific organs and tissues, enhancing the effectiveness of genetic therapies. This selective organ targeting (SORT) technology allows for the administration of corrective or disease-modifying treatments beyond the liver, addressing the challenges faced by traditional gene therapy methods. By harnessing these innovative techniques, ReCode Therapeutics aims to provide new therapeutic options for patients suffering from rare and life-limiting respiratory diseases.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

9amHealth is a healthcare service provider that aims to deliver comprehensive medical support for chronic conditions such as diabetes, hypertension, and hyperlipidemia. The company offers personalized care plans, prescription medication, at-home lab tests, and unlimited virtual visits, ensuring that patients have direct access to affordable and compassionate care. By redesigning all care elements into a single digital service, 9amHealth caters to the modern realities of patients' lives, making healthcare always available and convenient, even for those without insurance. Its focus on chronic conditions highlights its commitment to improving the health and well-being of customers in the United States.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Apollo Agriculture Ltd. is an agtech company based in Nairobi, Kenya, that supports smallholder farmers by providing financial and technical assistance. Founded in 2015, the company offers loans to help farmers acquire essential inputs such as fertilizer, seeds, and crop insurance, along with access to expert advice. By utilizing agronomic machine learning, remote sensing, and mobile technology, Apollo customizes financing packages based on individual farmer needs, assessing credit risk through satellite and soil data. This tailored approach aims to enhance farming practices and significantly increase crop yields, thereby maximizing profits for farmers in emerging markets.

Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.

Woebot Health is a digital mental healthcare provider that focuses on delivering personalized support through an innovative platform. This platform integrates advanced artificial intelligence and natural language processing with established therapeutic techniques to create engaging mental health tools. At the core of its offering is Woebot, a relational agent designed to provide continuous, empathic, and personalized care. By leveraging these technologies, Woebot Health enables individuals and businesses to access effective mental health support conveniently and seamlessly, fitting into everyday life and promoting overall well-being.

Founded in 2021, Cylinder delivers personalized, clinician-backed care to those suffering from digestive issues through its virtual health platform and has helped nearly 100K members to date. Cylinder's platform offers dynamically updated content and care plans designed to improve engagement and outcomes. Members enjoy access to a dedicated care team nationwide, including health coaches, registered dietitians, and GI doctors. Cylinder’s vision is to create a world where people receive convenient, personalized, and affordable access to the quality digestive health care they need to improve their overall health. Trusted by businesses including Texas A&M University, US Foods, and more, Cylinder showcases up to 5:1 ROI and an average of 13% employee engagement. Learn more at cylinderhealth.com.

Indapta Therapeutics is a privately held biotechnology company focused on developing a natural killer (NK) cell therapy platform aimed at treating both blood and solid tumor cancers. The company specializes in a proprietary off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the effectiveness of antibody therapies. Through its innovative approach, Indapta Therapeutics seeks to provide healthcare providers with advanced treatment options for patients suffering from cancer, leveraging the potent antibody-dependent cellular cytotoxicity (ADCC) activity of its NK cell therapy.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Gandeeva Therapeutics is a precision biotechnology company focused on developing innovative therapeutics by leveraging cryogenic electron microscopy and machine learning to target key protein-protein interactions. The company's structure-guided drug discovery platform includes target prediction and validation, hit identification through virtual and fragment library screening, and lead optimization. Gandeeva has established a strong preclinical oncology pipeline aimed at addressing challenging cancers with unique protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area, Canada, Gandeeva is dedicated to enhancing the drug discovery process and reducing the risk of late-stage clinical failures.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Bloom Science, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing neuroprotective medicines that leverage the microbiome to address epilepsy and other neurological conditions. Established in 2017, the company employs its proprietary IrisRx™ discovery platform, which utilizes insights into the Gut-Brain Axis to create therapeutics targeting rare and complex neurological disorders. This innovative approach aims to translate the therapeutic benefits of the ketogenic diet into effective medications, enhancing safety and efficacy. Bloom Science is advancing a diverse pipeline of therapeutic candidates aimed at conditions such as Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and various neurodegenerative and cognitive disorders, with a commitment to providing improved treatment options for patients facing serious, life-altering illnesses.

MedArrive, Inc. operates a software-as-a-service health platform that facilitates the extension of healthcare services into patients' homes. Based in New York, the company connects healthcare providers with a network of emergency medical professionals, allowing for a seamless integration of in-home care and telemedicine. This innovative approach aims to serve vulnerable populations by improving access to high-quality healthcare while reducing overall costs. MedArrive's platform consolidates clinical data into electronic medical records and enhances communication and billing processes, ultimately fostering better patient outcomes and encouraging self-advocacy among patients. By utilizing an underemployed workforce, MedArrive aims to bridge the virtual care gap, ensuring continuity of care and re-engaging patients in primary healthcare services.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

EarthOptics is a company focused on sustainable agricultural management through the development of a global soil cloud platform. Utilizing advanced sensors and machine learning, EarthOptics creates highly accurate soil maps by analyzing far fewer soil samples. The platform provides detailed insights into various soil attributes, including compaction, fertility, and carbon levels. This technology empowers farmers, ranchers, and land managers to make informed decisions that enhance profitability and sustainability in soil management. Additionally, EarthOptics offers near-real-time actionable data that aids in monitoring soil health, benefiting both agricultural practices and carbon credit verification efforts.

Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and farm revenues while addressing challenges such as drought. The company offers Source, a solution that enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby helping growers optimize crop performance sustainably. Additionally, Sound Agriculture focuses on improving photosynthesis, water capture, and crop efficiency, contributing to healthier and more flavorful food while reducing waste. Founded in 2012 and based in Emeryville, California, the company employs molecular discovery and life science approaches to create climate-resilient crops, ultimately enhancing productivity for farmers. Originally known as Asilomar Bio, Inc., it rebranded to Sound Agriculture Company in September 2018.

Andes develops an integrated microbial technology to help accelerate crop growth. Its technology is combined with artificial intelligence to develop its seeds while reducing input costs and environmental footprints and helps farmers to boost their agricultural output and income. Andes was founded in 2018 and is headquartered in Alameda, California.

Woebot Health is a digital mental healthcare provider that focuses on delivering personalized support through an innovative platform. This platform integrates advanced artificial intelligence and natural language processing with established therapeutic techniques to create engaging mental health tools. At the core of its offering is Woebot, a relational agent designed to provide continuous, empathic, and personalized care. By leveraging these technologies, Woebot Health enables individuals and businesses to access effective mental health support conveniently and seamlessly, fitting into everyday life and promoting overall well-being.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Ada Health is a global health company based in Berlin, Germany, founded in 2011 by a team of doctors, scientists, and industry experts. The company has developed a virtual health companion platform that empowers users to actively manage their health and assists medical professionals in delivering effective care. Ada's platform utilizes personalized health inquiries to assess symptoms and offers features such as online video consultations, disease monitoring, and prevention strategies. The company collaborates with leading health systems and global non-profit organizations to enhance healthcare delivery and improve health outcomes for individuals.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

Edifice Health is a company that originated from a decade-long research study on immune profiling conducted at Stanford University. It has developed a biomarker composite scoring system that assesses individual immune health and determines the Inflammatory Age®, a measure that predicts the onset of various chronic diseases. The company focuses on improving methods for measuring systemic chronic inflammation, which is crucial for enhancing inflammatory and immune health. Edifice Health's innovative approach integrates applications in personalized nutritional and immunological science, leveraging AI-powered technology to aid healthcare professionals in the early detection of systemic chronic inflammation. This technology aims to provide comprehensive health insights that empower individuals to alter their aging trajectory and promote healthier aging.

Guardian Agriculture specializes in developing autonomous electric vertical takeoff and landing (eVTOL) systems tailored for precision agriculture. Their innovative technology empowers farmers by providing automated aerial crop protection services, significantly enhancing operational efficiency while minimizing environmental impact. The eVTOL system utilizes lithium battery power to ensure safe and effective application over farm fields. Additionally, it captures valuable data to help farmers refine their chemical usage and improve crop sustainability. By integrating aerial utility services with precision agriculture, Guardian Agriculture aims to support growers in extending their operational reach and achieving more sustainable farming practices.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Grão Direto LTDA operates a digital trading platform that facilitates the buying and selling of grains, connecting farmers and grain buyers in a more efficient manner. Founded in 2016 and based in Uberaba, Brazil, the platform enables users to negotiate and finalize deals for spot, future, or barter trades. It enhances market intelligence, allowing producers and buyers to make informed decisions regarding pricing and grain selection. Additionally, Grão Direto supports various processes related to grain trading, including logistics, contract management, and financial products. The platform is accessible via both a web interface and a smartphone application, catering to a diverse range of users, including cooperatives, trading companies, traditional brokers, and warehouses. By integrating technology into grain commercialization, Grão Direto aims to modernize the agricultural commodity chain in Brazil and beyond.

Amfora, Inc. is a biotechnology company based in San Francisco, California, established in 2016. The company focuses on developing nutritional forage crops through innovative biotechnological processes, particularly gene editing. Its mission is to address the increasing global demand for high-protein foods by enhancing the nutritional density of crops such as soybeans, wheat, and rice. By improving the protein content of these food and feed crops, Amfora aims to contribute to a more sustainable food system, reducing both costs and the environmental impact associated with food production.

Pairwise Plants is an agricultural gene editing company based in San Diego, California, focused on enhancing crops such as corn, soybeans, wheat, cotton, and canola. Founded in 2017 by a team of experts in food technology and genetics, Pairwise aims to improve the quality and nutritional value of fruits and vegetables, including leafy greens, berries, and stone fruits. The company collaborates with food and agriculture organizations to provide innovative solutions for both row and specialty crops. Pairwise holds licenses for advanced gene editing technologies from prestigious institutions, enabling the development of new crop varieties. With a commitment to building a healthier world through better food, Pairwise anticipates launching its first products in the coming years.

Ukko is a biotechnology company focused on enhancing the lives of individuals with food allergies and gluten-related disorders. Utilizing a sophisticated computational engineering platform, Ukko redesigns food allergens into therapeutics that are safe and effective. The company is developing a detailed, clinically validated map of the molecular structures associated with food allergies, which provides insights into the biological mechanisms of human-food interactions. By leveraging this information, Ukko creates modified proteins that do not provoke an immune response, offering a novel approach to treating protein-based allergies. Through the integration of artificial intelligence, immunology, computational biology, and protein engineering, Ukko aims to produce safe protein alternatives that physicians can confidently prescribe to patients.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Rantizo, Inc. is a company that specializes in the development and sale of agricultural drones and related equipment, including trailers, sprayers, spreaders, and battery chargers. Founded in 2018 and based in Iowa City, Iowa, Rantizo offers precision spraying services for crops using an innovative electrostatic spraying technique. This technology ensures even coverage of pesticides and chemicals, addressing common challenges faced by farmers in applying these substances. Additionally, Rantizo integrates software solutions with drone manufacturers and agronomy systems to enhance large-scale agricultural operations, facilitating efficient mapping, compliance, and coordination of spraying needs. Through its products and services, Rantizo aims to streamline agricultural practices and improve crop management for farmers.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, focused on developing microbiome-based therapeutics for skin diseases. Established in 2014, Azitra leverages its proprietary platform, which includes a microbial library of bacterial strains, to discover and create novel treatments for adverse skin conditions. The company's technology, developed in collaboration with researchers at Yale University and the Jackson Laboratory, is centered around a specific strain of the natural commensal bacteria Staphylococcus epidermidis. Additionally, Azitra employs artificial intelligence and machine learning to enhance the screening and prediction of therapeutic characteristics within its microbial library. By utilizing engineered proteins and live biotherapeutic products for topical application, Azitra aims to advance precision dermatology.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Salt Lake City, Utah, that focuses on revolutionizing drug discovery through the integration of advanced technologies such as artificial intelligence, automation, and bioinformatics. Founded in 2013, the company has developed a comprehensive drug discovery platform that includes various tools and software, such as ReChem for chemical compound design, ReScreen for managing complex experimental workflows, and RePredict for modeling drug relationships using machine learning. These innovations enable Recursion to generate extensive biological and chemical datasets, facilitating the exploration of foundational biology and accelerating the development of new therapeutic solutions. Through its unique approach, Recursion aims to significantly enhance patient outcomes and streamline the drug discovery process.

Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.

Unfold Bio, Inc. specializes in developing seeds for indoor vertical farming, offering varieties such as lettuce, spinach, cucumbers, tomatoes, and peppers. Founded in 2020 and based in Sacramento, California, the company utilizes advanced seed genetics and agronomic expertise to enhance productivity and flavor, catering to the growing vertical farming market. Its innovative approach allows for optimal water use, minimizes reliance on synthetic inputs, and facilitates food production in environments with limited arable land. Unfold collaborates with vertical farming operators, technology providers, and stakeholders across the produce supply chain to foster a sustainable local food culture. The company also conducts research and development operations in California and Singapore, aiming to improve food variety and consumer experiences in the industry.

Vesigen Therapeutics is a biotechnology company focused on developing innovative therapeutic products that address the challenges of targeted intracellular drug delivery. The company's proprietary technology, known as ARMMs (ARRDC1 Mediated Microvesicles), facilitates the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This capability allows for an expanded range of druggable targets and supports the development of new therapies aimed at meeting currently unmet medical needs. By enhancing the delivery mechanisms for next-generation therapeutics, Vesigen Therapeutics aims to contribute significantly to advancements in the field of medicine.

Apollo Agriculture Ltd. is an agtech company based in Nairobi, Kenya, that supports smallholder farmers by providing financial and technical assistance. Founded in 2015, the company offers loans to help farmers acquire essential inputs such as fertilizer, seeds, and crop insurance, along with access to expert advice. By utilizing agronomic machine learning, remote sensing, and mobile technology, Apollo customizes financing packages based on individual farmer needs, assessing credit risk through satellite and soil data. This tailored approach aims to enhance farming practices and significantly increase crop yields, thereby maximizing profits for farmers in emerging markets.

CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

Oerth Bio LLC is a biotechnology company focused on developing innovative solutions for crop protection through the use of targeted protein degraders. Founded in 2019 and based in Durham, North Carolina, the company utilizes PROTAC (proteolysis targeting chimeras) technology to create effective agricultural applications. This approach allows Oerth Bio to enhance crop yields while reducing reliance on harmful pesticides, ultimately promoting sustainable agricultural practices. By targeting protein degraders, the company aims to produce cleaner and healthier crops, contributing to the overall improvement of agricultural efficiency and safety.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

BlueRock Therapeutics LP is a biotechnology company focused on developing engineered cell therapies utilizing its CELL+GENE platform. Founded in 2016 and headquartered in Cambridge, Massachusetts, with additional offices in New York and Toronto, the company specializes in induced pluripotent stem cell (iPSC) therapies aimed at treating various diseases, particularly in the fields of neurology, cardiology, and immunology. One of its key initiatives involves regenerating heart muscle in patients who have experienced heart attacks or suffer from chronic heart failure, addressing significant health challenges. BlueRock also offers stable master cell banks, including healthy donor cells and methods for immune evasion, to support its therapeutic development efforts. As of September 2019, BlueRock operates as a subsidiary of Bayer Aktiengesellschaft.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Resson is a bioinformatics and data analytics company based in Fredericton, New Brunswick, specializing in customized agriculture solutions for large corporate clients. The company employs advanced technologies such as cloud-based data processing, swarm robotics, computer vision, and machine learning to enhance agricultural productivity. Its proprietary platform, the Resson Agricultural Management and Analytics System, analyzes crop metrics to assess the health and status of crops. By providing actionable insights derived from field data, Resson enables agricultural operators to optimize their operations, improve efficiency, increase yields, and maximize profitability.

Pairwise Plants is an agricultural gene editing company based in San Diego, California, focused on enhancing crops such as corn, soybeans, wheat, cotton, and canola. Founded in 2017 by a team of experts in food technology and genetics, Pairwise aims to improve the quality and nutritional value of fruits and vegetables, including leafy greens, berries, and stone fruits. The company collaborates with food and agriculture organizations to provide innovative solutions for both row and specialty crops. Pairwise holds licenses for advanced gene editing technologies from prestigious institutions, enabling the development of new crop varieties. With a commitment to building a healthier world through better food, Pairwise anticipates launching its first products in the coming years.

Joyn Bio LLC is a joint venture established by Bayer and Ginkgo Bioworks, focusing on the development of microbial probiotics for plants. Founded in 2017 and headquartered in Boston, Massachusetts, with a research facility in West Sacramento, California, the company aims to tackle significant agricultural challenges. Its primary initiative involves engineering microbes that help cereal crops like corn, wheat, and rice meet their nitrogen needs. This innovation seeks to reduce the agricultural sector's dependence on nitrogen fertilizers, thereby minimizing the environmental impact associated with chemical fertilizer usage. Joyn Bio's multidisciplinary team includes microbiologists, synthetic biologists, plant scientists, and ecologists dedicated to advancing sustainable agricultural practices.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

FarmLead Resources Ltd. is a digital marketplace designed to enhance the buying and selling of grain, connecting farmers with verified buyers across North America. Founded in 2013 and based in Ottawa, Canada, the company operates in key agricultural regions including Alberta, Saskatchewan, Manitoba, and Ontario. Through its online platform and mobile application, FarmLead offers various services such as market research, grain testing, and price visibility, which help reduce brokerage fees and risks for farmers. The marketplace promotes efficiency, transparency, and equality within the grain industry, enabling farmers to negotiate better deals while allowing buyers to conveniently find the grain they need in their preferred locations.

BlueRock Therapeutics LP is a biotechnology company focused on developing engineered cell therapies utilizing its CELL+GENE platform. Founded in 2016 and headquartered in Cambridge, Massachusetts, with additional offices in New York and Toronto, the company specializes in induced pluripotent stem cell (iPSC) therapies aimed at treating various diseases, particularly in the fields of neurology, cardiology, and immunology. One of its key initiatives involves regenerating heart muscle in patients who have experienced heart attacks or suffer from chronic heart failure, addressing significant health challenges. BlueRock also offers stable master cell banks, including healthy donor cells and methods for immune evasion, to support its therapeutic development efforts. As of September 2019, BlueRock operates as a subsidiary of Bayer Aktiengesellschaft.

Resson is a bioinformatics and data analytics company based in Fredericton, New Brunswick, specializing in customized agriculture solutions for large corporate clients. The company employs advanced technologies such as cloud-based data processing, swarm robotics, computer vision, and machine learning to enhance agricultural productivity. Its proprietary platform, the Resson Agricultural Management and Analytics System, analyzes crop metrics to assess the health and status of crops. By providing actionable insights derived from field data, Resson enables agricultural operators to optimize their operations, improve efficiency, increase yields, and maximize profitability.

Plant Response is a developer of agricultural technologies focused on enhancing plant health and growth through biological solutions. The company utilizes natural compounds to create products that improve plant immunity, increase tolerance to environmental stresses, and optimize nutrient use. By leveraging technology initially developed by researchers at the CBGP, Plant Response aims to address the challenges faced in modern agriculture and provide effective crop protection solutions. Their innovations are designed to meet the evolving needs of agricultural professionals globally, contributing to the restoration and advancement of the agricultural ecosystem.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.